Trailblazing work with 3D Human Liver Models Yields Accurate MASH (formerly NASH) Phenotype

Viscient has leveraged model to develop novel MASH therapies SAN DIEGO, Jan. 23, 2024 /PRNewswire/ — Viscient Biosciences (“Viscient”) today announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks